AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34328473 — intervention group
Group type: COMPARATOR
Intervention: PM+MA
Number of subjects: 42
Study 34530161 — intervention group
Group type: EXPERIMENTAL
Intervention: CADe colonoscopy first
Number of subjects: 223
Study 34530161 — intervention group
Group type: COMPARATOR
Intervention: HDWL colonoscopy first
Number of subjects: 223
Study 32437074 — intervention group
Group type: EXPERIMENTAL
Intervention: Isavuconazole
Number of subjects: 0
Study 32437074 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole
Number of subjects: 0
Study 32437074 — intervention group
Group type: EXPERIMENTAL
Intervention: Voriconazole
Number of subjects: 0
Study 32437074 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole
Number of subjects: 0
Study 34981592 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Centeredness Index (PCI) survey administered to patients with chronic conditions
Number of subjects: 3622
Study 33812692 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound training program (2 weeks on-site training)
Number of subjects: 18
Study 33059420 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified conjunctival transplantation and amniotic membrane transplantation combined with use of IFN alpha‐2b eye drops
Number of subjects: 70
Study 33059420 — intervention group
Group type: COMPARATOR
Intervention: Pterygium resection combined with conjunctival autograft transplantation
Number of subjects: 70
Study 33059420 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 70
Study 33891473 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab with or without cobimetinib (experimental arm of IMblaze370)
Number of subjects: 292
Study 33891473 — intervention group
Group type: COMPARATOR
Intervention: Control arm of IMblaze370 (regorafenib)
Number of subjects: 292
Study 33891473 — intervention group
Group type: COMPARATOR
Intervention: Flatiron Health EC
Number of subjects: 292
Study 33891473 — intervention group
Group type: COMPARATOR
Intervention: Clinico-Genomic Database EC
Number of subjects: 292
Study 35986403 — intervention group
Group type: EXPERIMENTAL
Intervention: Tuina treatment
Number of subjects: 60
Study 35986403 — intervention group
Group type: COMPARATOR
Intervention: Healthcare education group (Control)
Number of subjects: 60
Study 32239336 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% ACV (T1)
Number of subjects: 180
Study 32239336 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% ACV (T2)
Number of subjects: 180
Study 32239336 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% ACV (T3)
Number of subjects: 180
Study 32239336 — intervention group
Group type: COMPARATOR
Intervention: 0% ACV (Control)
Number of subjects: 180
Study 616118370 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mug/d FAc
Number of subjects: 321
Study 616118370 — intervention group
Group type: COMPARATOR
Intervention: Sham injection (control)
Number of subjects: 321
Study 34155773 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic Medical Record (EMR)
Number of subjects: 200
Study 34155773 — intervention group
Group type: EXPERIMENTAL
Intervention: My Health Record (MHR)
Number of subjects: 200
Study 34155773 — intervention group
Group type: COMPARATOR
Intervention: EMR and MHR
Number of subjects: 200
Study 33283581 — intervention group
Group type: EXPERIMENTAL
Intervention: Focused shock waves (F-SW) 1500 shocks
Number of subjects: 45
Study 33283581 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial shock waves (R-SW) 2000 shocks
Number of subjects: 45
Study 33283581 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined focused and radial shock waves (C-SW)
Number of subjects: 45
Study 34806486 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus feeding (BF group, n=24)
Number of subjects: 46
Study 34806486 — intervention group
Group type: COMPARATOR
Intervention: Continuous feeding (CF group, n=22)
Number of subjects: 46
Study 33704620 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin 40 mg/m2 and lurbinectedin 2.0 mg/m2 on Day 1 q3wk
Number of subjects: 28
Study 33704620 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin 40 mg/m2 and lurbinectedin 2.0 mg/m2 on Day 1 q3wk in sensitive disease
Number of subjects: 28
Study 33704620 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin 40 mg/m2 and lurbinectedin 2.0 mg/m2 on Day 1 q3wk in resistant disease
Number of subjects: 28
Study 32914838 — intervention group
Group type: EXPERIMENTAL
Intervention: Text messaging-based HPV vaccination intervention (txt2protect)
Number of subjects: 150
Study 32914838 — intervention group
Group type: COMPARATOR
Intervention: Control condition messages focused on a variety of sexual health practices
Number of subjects: 150
Study 32852553 — intervention group
Group type: EXPERIMENTAL
Intervention: Education and personalized text message reminders daily to prompt directly supervised therapy (intervention group)
Number of subjects: 444
Study 32852553 — intervention group
Group type: COMPARATOR
Intervention: Education alone (control group)
Number of subjects: 444
Study 33528110 — intervention group
Group type: EXPERIMENTAL
Intervention: Partially guided template (test group 1, 36 implants)
Number of subjects: 60
Study 33528110 — intervention group
Group type: EXPERIMENTAL
Intervention: Fully guided template (test group 2, 33 implants)
Number of subjects: 60
Study 33528110 — intervention group
Group type: COMPARATOR
Intervention: Routine implant‐supported restoration treatment (control group, 30 implants)
Number of subjects: 60
Study 33528110 — intervention group
Group type: EXPERIMENTAL
Intervention: Partially guided template (test group 1)
Number of subjects: 60
Study 33528110 — intervention group
Group type: EXPERIMENTAL
Intervention: Fully guided template (test group 2)
Number of subjects: 60
Study 32875431 — intervention group
Group type: EXPERIMENTAL
Intervention: 2D convolutional neural network (CNN) using sagittal scans from the SCIENCe cohort.
Number of subjects: 155
Study 32875431 — intervention group
Group type: EXPERIMENTAL
Intervention: 2D convolutional neural network (CNN) using ADNI scans as test set.
Number of subjects: 155
Study 35963146 — intervention group
Group type: EXPERIMENTAL
Intervention: High salience of base-rate information
Number of subjects: 368
Study 35963146 — intervention group
Group type: EXPERIMENTAL
Intervention: Low salience of base-rate information
Number of subjects: 368
Study 35963146 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-related problems
Number of subjects: 368
Study 35963146 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-neutral problems
Number of subjects: 368
Study 33307847 — intervention group
Group type: EXPERIMENTAL
Intervention: Full Moon (FM)
Number of subjects: 42
Study 33307847 — intervention group
Group type: EXPERIMENTAL
Intervention: New Moon (NM)
Number of subjects: 42
Study 33307847 — intervention group
Group type: EXPERIMENTAL
Intervention: Static exercise during New Moon (NM)
Number of subjects: 42
Study 33307847 — intervention group
Group type: EXPERIMENTAL
Intervention: Static exercise during Full Moon (FM)
Number of subjects: 42
Study 33307847 — intervention group
Group type: COMPARATOR
Intervention: First Quarter (FQ)
Number of subjects: 42
Study 33307847 — intervention group
Group type: COMPARATOR
Intervention: Third Quarter (TQ)
Number of subjects: 42
Study 35504257 — intervention group
Group type: EXPERIMENTAL
Intervention: CARS system
Number of subjects: 163
Study 35504257 — intervention group
Group type: COMPARATOR
Intervention: FDI recurrence of caries
Number of subjects: 163
Study 35504257 — intervention group
Group type: COMPARATOR
Intervention: FDI marginal adaptation
Number of subjects: 163
Study 35504257 — intervention group
Group type: COMPARATOR
Intervention: FDI marginal staining
Number of subjects: 163
Study 35504257 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up restorations
Number of subjects: 163
Study 33771945 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% carbohydrate (CHO) drink
Number of subjects: 10
Study 33771945 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 32862007 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (40 i.u.)
Number of subjects: 0
Study 32862007 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 36892754 — intervention group
Group type: EXPERIMENTAL
Intervention: Fesoterodine 4 mg once daily (QD) for patients weighing 25–35 kg
Number of subjects: 142
Study 36892754 — intervention group
Group type: EXPERIMENTAL
Intervention: Fesoterodine 8 mg once daily (QD) for patients weighing > 35 kg
Number of subjects: 142
Study 36892754 — intervention group
Group type: COMPARATOR
Intervention: Fesoterodine 8 mg once daily (QD) for adults
Number of subjects: 142
Study 33106606 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐ELS 40 (40 ml/kg)
Number of subjects: 150
Study 33106606 — intervention group
Group type: COMPARATOR
Intervention: PEG‐ELS 60 (60 ml/kg)
Number of subjects: 150
Study 34900203 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-Body Vibration Training (WBVT)
Number of subjects: 32
Study 32579674 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinship judgments (related or unrelated)
Number of subjects: 318
Study 32579674 — intervention group
Group type: EXPERIMENTAL
Intervention: Similarity judgments (scale from 0 to 10)
Number of subjects: 318
Study 32579674 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinship judgments
Number of subjects: 318
Study 32579674 — intervention group
Group type: EXPERIMENTAL
Intervention: Similarity judgments
Number of subjects: 318
Study 34407645 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 22
Study 34407645 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 22
Study 34407645 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 32250198 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 0
Study 32250198 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35382059 — intervention group
Group type: EXPERIMENTAL
Intervention: IV dexmedetomidine 1 µg/kg over 10 min
Number of subjects: 60
Study 35382059 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 60
Study 33740610 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative Index (QI)
Number of subjects: 155
Study 33740610 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative Evaluation (QE)
Number of subjects: 155
Study 33740610 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall Adequacy Assessment (OAA)
Number of subjects: 155
Study 35266219 — intervention group
Group type: EXPERIMENTAL
Intervention: FGE dark chocolate (5 g/day containing 650 mg of FGE powder)
Number of subjects: 36
Study 35266219 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 32016118 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal Bevacizumab (IVB) plus topical dorzolamide 2% twice daily
Number of subjects: 16
Study 32016118 — intervention group
Group type: COMPARATOR
Intervention: Intravitreal Bevacizumab (IVB) alone plus topical artificial tear twice daily
Number of subjects: 16
Study 34081625 — intervention group
Group type: EXPERIMENTAL
Intervention: Psyllium husk
Number of subjects: 54
Study 34081625 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 32030910 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-regulation intervention
Number of subjects: 340
Study 32030910 — intervention group
Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 340
Study 616791213 — intervention group
Group type: EXPERIMENTAL
Intervention: Sanitary pad containing potassium alum
Number of subjects: 16
Study 616791213 — intervention group
Group type: COMPARATOR
Intervention: Ordinary sanitary pads
Number of subjects: 16
Study 35260538 — intervention group
Group type: EXPERIMENTAL
Intervention: Water with electrolytes (169 oz / 5L)
Number of subjects: 30
Study 35260538 — intervention group
Group type: COMPARATOR
Intervention: Plain water (169 oz / 5L)
Number of subjects: 30
Study 35260538 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified, but implied as baseline monitoring)
Number of subjects: 30
Study 33039340 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydralazine-isosorbide dinitrate
Number of subjects: 1500
Study 33039340 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 1500
Study 33039340 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1500
Study 32602065 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime–avibactam ± metronidazole
Number of subjects: 4050
Study 32602065 — intervention group
Group type: COMPARATOR
Intervention: Comparator
Number of subjects: 4050
Study 36082955 — intervention group
Group type: EXPERIMENTAL
Intervention: Power prior models applied to first stage outcomes
Number of subjects: 0
Study 36082955 — intervention group
Group type: EXPERIMENTAL
Intervention: Fisher's Exact Test
Number of subjects: 0
Study 36082955 — intervention group
Group type: EXPERIMENTAL
Intervention: Bhattacharyya's overlap measure
Number of subjects: 0
Study 32034024 — intervention group
Group type: EXPERIMENTAL
Intervention: Helping Families Programme‐Modified (HFP‐M)
Number of subjects: 48
Study 32034024 — intervention group
Group type: COMPARATOR
Intervention: Usual care (standard care augmented by a single psychoeducational parenting session)
Number of subjects: 48
Study 32034024 — intervention group
Group type: EXPERIMENTAL
Intervention: HFP‐M
Number of subjects: 48
Study 32034024 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 48
Study 33476595 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytoreductive surgery plus HIPEC (360 mg/m2 closed abdomen or 460 mg/m2 open abdomen)
Number of subjects: 265
Study 33476595 — intervention group
Group type: COMPARATOR
Intervention: Cytoreductive surgery alone
Number of subjects: 265
Study 35974312 — intervention group
Group type: EXPERIMENTAL
Intervention: Single vision spectacle lenses with concentric rings of slightly aspherical contiguous lenslets technology (SAL)
Number of subjects: 100
Study 35974312 — intervention group
Group type: COMPARATOR
Intervention: Single vision lenses
Number of subjects: 100
Study 32841748 — intervention group
Group type: EXPERIMENTAL
Intervention: Epicutaneous immunotherapy (DBV712 250 μg, daily epicutaneous peanut protein)
Number of subjects: 253
Study 32841748 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 253
Study 35257614 — intervention group
Group type: EXPERIMENTAL
Intervention: Linear mixed effects model with random time effects
Number of subjects: 0
Study 35257614 — intervention group
Group type: EXPERIMENTAL
Intervention: Linear mixed effects model with random treatment effects
Number of subjects: 0
Study 35257614 — intervention group
Group type: EXPERIMENTAL
Intervention: Correctly specified model
Number of subjects: 0
Study 35257614 — intervention group
Group type: EXPERIMENTAL
Intervention: Classic stepped wedge cluster randomized trial with only 2 sequences
Number of subjects: 0
Study 35141396 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 Hz transcranial alternating current stimulation (tACS) for 30 days, 1-hour daily sessions
Number of subjects: 50
Study 35141396 — intervention group
Group type: COMPARATOR
Intervention: Sham (placebo) tACS
Number of subjects: 50
Study 35141396 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 Hz transcranial alternating current stimulation (tACS)
Number of subjects: 50
Study 36147126 — intervention group
Group type: EXPERIMENTAL
Intervention: HES 130/0.4
Number of subjects: 60
Study 36147126 — intervention group
Group type: COMPARATOR
Intervention: Ringer's bicarbonate
Number of subjects: 60
Study 33150355 — intervention group
Group type: EXPERIMENTAL
Intervention: Caplacizumab
Number of subjects: 85
Study 36106828 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention articles acknowledging the suicide (discussion with a psychologist, a friend of the decedent, or a suicide survivor)
Number of subjects: 425
Study 36106828 — intervention group
Group type: COMPARATOR
Intervention: Control article (no mention of the suicide)
Number of subjects: 425
Study 34481729 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled allergen-specific IgE antibody positivity measurement
Number of subjects: 800
Study 34481729 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific IgE antibodies to inhaled allergens
Number of subjects: 800
Study 34481729 — intervention group
Group type: EXPERIMENTAL
Intervention: IgE measurement to Japanese cedar pollen, D. pteronyssinus, and moths
Number of subjects: 800
Study 34481729 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional differences in pollen IgE positivity
Number of subjects: 800
Study 33919529 — intervention group
Group type: EXPERIMENTAL
Intervention: Health literacy intervention
Number of subjects: 799
Study 33919529 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention
Number of subjects: 799
Study 33919529 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined health literacy and exercise intervention
Number of subjects: 799
Study 33919529 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity (PA) levels
Number of subjects: 799
Study 32945537 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenfluramine hydrochloride (FFA), administered as add-on, twice daily at an initial dose of 0.2 mg/kg/d up to 0.7 mg/kg/d
Number of subjects: 52
Study 32945537 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenfluramine hydrochloride (FFA)
Number of subjects: 52
Study 33834887 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramedullary nail (IMN) fixation
Number of subjects: 16
Study 33834887 — intervention group
Group type: COMPARATOR
Intervention: K-wire fixation
Number of subjects: 16
Study 33624705 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol (N=18)
Number of subjects: 32
Study 33624705 — intervention group
Group type: COMPARATOR
Intervention: Placebo (N=14)
Number of subjects: 32
Study 33624705 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol (150 nM) in vitro
Number of subjects: 32
Study 33624705 — intervention group
Group type: COMPARATOR
Intervention: Uremic serum in vitro
Number of subjects: 32
Study 35057591 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilnidipine
Number of subjects: 100
Study 35057591 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 100
Study 33422704 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher genetically predicted education
Number of subjects: 388051
Study 33422704 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher genetically predicted LDL-C levels
Number of subjects: 388051
Study 33422704 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher genetically predicted BMI
Number of subjects: 388051
Study 33422704 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher genetically predicted smoking
Number of subjects: 388051
Study 33422704 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher genetically predicted SBP
Number of subjects: 388051
Study 33422704 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically predicted education mediated through genetically predicted BMI and smoking
Number of subjects: 388051
Study 33917677 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated oral healthcare intervention (dental assistance and collective health education actions in conversation circles)
Number of subjects: 146
Study 33917677 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual assistance)
Number of subjects: 146
Study 33917677 — intervention group
Group type: EXPERIMENTAL
Intervention: Low educational level of pregnant women
Number of subjects: 146
Study 33917677 — intervention group
Group type: EXPERIMENTAL
Intervention: Low family income (≤261.36 USD)
Number of subjects: 146
Study 33228667 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-led community-based intervention for awareness generation on maternal and child health (MCH)
Number of subjects: 37324
Study 33228667 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-led community-based intervention for livelihood scheme registration
Number of subjects: 37324
Study 33228667 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-led community-based intervention for livelihood scheme participation
Number of subjects: 37324
Study 33228667 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-led community-based intervention for women's awareness about MCH
Number of subjects: 37324
Study 33228667 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-led community-based intervention for savings and financial management
Number of subjects: 37324
Study 35260354 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic azithromycin
Number of subjects: 129
Study 35260354 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 129
Study 33129157 — intervention group
Group type: EXPERIMENTAL
Intervention: Prompt Mental Health Care (PMHC)
Number of subjects: 681
Study 33129157 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 681
Study 33129157 — intervention group
Group type: EXPERIMENTAL
Intervention: PMHC
Number of subjects: 681
Study 32713797 — intervention group
Group type: EXPERIMENTAL
Intervention: Osia®
Number of subjects: 8
Study 32713797 — intervention group
Group type: COMPARATOR
Intervention: Baha® Attract
Number of subjects: 8
Study 32602742 — intervention group
Group type: EXPERIMENTAL
Intervention: Match-day (MD+1) assessment of mental fatigue (43±1 mm)
Number of subjects: 10
Study 32602742 — intervention group
Group type: EXPERIMENTAL
Intervention: Late-season phase (MD+1) mental fatigue (34±2 mm)
Number of subjects: 10
Study 32602742 — intervention group
Group type: EXPERIMENTAL
Intervention: Match success rate in late-season (80%)
Number of subjects: 10
Study 32602742 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlations between changes in MF and wellness variables
Number of subjects: 10
Study 33368855 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 0
Study 33368855 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35962351 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared decision-making tool about anticoagulation
Number of subjects: 922
Study 35962351 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 922
Study 34164852 — intervention group
Group type: EXPERIMENTAL
Intervention: Boarding phase
Number of subjects: 52
Study 34164852 — intervention group
Group type: EXPERIMENTAL
Intervention: Cruising phase
Number of subjects: 52
Study 34164852 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimated outside airflow rates in economy class
Number of subjects: 52
Study 34164852 — intervention group
Group type: COMPARATOR
Intervention: Comparison with previous studies
Number of subjects: 52